These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37753246)

  • 1. Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis.
    Saba NJ; Walter SD
    Clin Ophthalmol; 2023; 17():2791-2802. PubMed ID: 37753246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Heier JS; Khanani AM
    Ophthalmology; 2024 Sep; ():. PubMed ID: 39182627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
    Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
    Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review.
    Giunta M; Gauvin Meunier LP; Nixon D; Steeves J; Noble J
    Clin Ophthalmol; 2022; 16():2885-2894. PubMed ID: 36065355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
    Coney JM; Zubricky R; Sinha SB; Sonbolian N; Zhou L; Hull TP; Lewis SA; Miller DG; Novak MA; Pendergast SD; Pham H; Platt SM; Rao LJ; Schartman JP; Singerman LJ; Donkor R; Fink M; McCoy J; Karcher H
    Int J Retina Vitreous; 2023 Feb; 9(1):8. PubMed ID: 36726178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
    Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
    Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
    Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
    Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study.
    Chakraborty D; Maiti A; Sheth JU; Boral S; Mondal S; Nandi K; Sinha T; Das A
    Clin Ophthalmol; 2021; 15():3787-3795. PubMed ID: 34522081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.